Figure 4.

(a) Involvement of NK₁ receptors, mast cells and PMN adhesion in neurogenic and SP-induced oedema. The NK₁ receptor antagonist, L-703,606 (0.5 mg kg⁻¹ i.v.), the mast cell stabilizer, cromolyn (5 mg kg⁻¹ i.v.), the H₁ receptor antagonist, mepyramine (6 mg kg⁻¹ i.v.), or the polysaccharide fucoidan (5 mg kg⁻¹ i.v.) were injected 15 min before a 5-min stimulation (neurogenic oedema). L-703,606 (1 μg site⁻¹ i.d.), cromolyn (10 μg site⁻¹ i.d.), mepyramine (1 μg site⁻¹ i.d.), or fucoidan (10 μg site⁻¹ i.d.) were co-injected with SP (100 pmol site⁻¹ i.d., SP-induced oedema) or compound 48/80 (1 μg site⁻¹ i.d.; compound 48/80-induced oedema). The anti-inflammatory effects are expressed as per cent inhibition of the oedema volume in untreated animals (see Methods). Asterisks indicate significant differences in volume of neurogenic or SP-induced oedema between treated and untreated animals. (^*P<0.05, ^**P<0.01 according to ANOVA, followed by Bonferroni's test for multiple comparisons). (b) Effect of LOX and COX pathway inhibitors on compound 48/80-induced oedema. Drugs were co-injected with compound 48/80 (1 μg site⁻¹ i.d.), at the same doses used in Figures 1 and 3 for SP-induced oedema. The anti-inflammatory effects are expressed as per cent inhibition of the oedema volume in untreated animals (see Methods). Asterisks indicate significant differences in the volume of compound 48/80-induced oedema between treated and untreated animals. (^*P<0.05 according to ANOVA, followed by Bonferroni's test for multiple comparisons).